Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SA Transcripts 162.21K Followers Follow Intellia Therapeutics, Inc. ( NTLA ) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:05 PM EDT Company Participants John Leonard - President, CEO & Director Edward Dulac - Executive VP, CFO & Treasurer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Morgan Stanley, Research Division All right. Well, thanks, everyone, for joining us. I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. So I'm very pleased to be hosting Intellia today. Joining us from the company, we have John Leonard, the company's CEO; and Ed Dulac, who's the company's CFO. Thank you both for being here. Really appreciate it. Looking forward to speaking with you. Question-and-Answer Session Terence Flynn Morgan Stanley, Research Division I thought we'd start maybe just high level, John, to talk about in vivo editing and just the potential for the platform. I think, again, there's been a lot of -- the technology has been in development for a long time now. We're starting to see really impressive use cases here. And so as you think about the potential, maybe just talk to us about high level, where you think this can go over time and then some of the outstanding hurdles to really effectively scale it? And then we'll get into your more specific pipeline for sure. John Leonard President, CEO & Director Thanks for the question, and happy to be here. We pioneered the in vivo gene editing space. I mean, in the early days, as CRISPR was coming to be, I think a lot of people went off into ex vivo and started off in that space. We bit the bullet and went directly to the in vivo editing